Milene Brownlow

Milene Brownlow

Auto-generated profile, based on publicly available information

Milene Brownlow

Center for Scientific Review,Bethesda,United States, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2023 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
ABAlex Buga
Alex Buga
Madison Lee KackleyMadison Lee Kackley
Madison Lee Kackley
CCChristopher Crabtree
Christopher Crabtree
TBTeryn Bedell
Teryn Bedell
BRBradley T. Robinson
Bradley T. Robinson
JVJeff Volek
Jeff Volek

1 July 2015 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
VDVedad Delic
Vedad Delic
MBMilene Lara Brownlow
Milene Lara Brownlow
AJAurelie Joly-Amado
Aurelie Joly-Amado
SZSandra Zivkovic
Sandra Zivkovic
KNKenyaria Noble
Kenyaria Noble
PBPatrick C. Bradshaw
Patrick C. Bradshaw

10 February 2022 in Neurochemistry International
Verified
Journal Article
Closed access
AMAndressa Busetti Martins
Andressa Busetti Martins
MBMilene Lara Brownlow
Milene Lara Brownlow
BABruno Blanco Araújo
Bruno Blanco Araújo
MGMarcela Cristina Garnica-Siqueira
Marcela Cristina Garnica-Siqueira
DZDimas Augusto Morozin Zaia
Dimas Augusto Morozin Zaia
EUErnane Uchoa
Ernane Uchoa

21 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ACAshwini Chebbi
Ashwini Chebbi
GHGemma Huber
Gemma Huber
MMMona Mchaourab
Mona Mchaourab
CPChiara Marie Petrazzuolo-Leiva
Chiara Marie Petrazzuolo-Leiva
AMAriana Rose Mallernee
Ariana Rose Mallernee
Madison Lee KackleyMadison Lee Kackley
Madison Lee Kackley
Background: The SPARK (Symptoms of PCOS ameliorated by responses to Ke-to-adaptation) pilot study investigates whether nutritional ketosis can improve repro-ductive and metabolic outcomes in women with Polyendocrine Metabolic Ovarian Syndrome (PMOS). PMOS is a common endocrinopathy characterized by anovulation, hyperandrogenism, and metabolic dysfunction. Objective: To evaluate if a ketogenic diet (KD) or exogenous ketone supplementation (KS) with Qitone™ (bis-octanoyl-(R)-1,3-butanediol) can restore ovulation and menstrual activity. Methods: This ongoing 12-week randomized trial assigns women with PMOS to either a KD or KS intervention. Assessments include body composition by DXA, metabolic and reproduc-tive biomarkers (e.g., insulin, testosterone, SHBG), and cycle tracking via basal body temperature. Results: Preliminary data from seven participants (KD: n=3; KS: n=4) show that 100% demonstrated spontaneous menstrual activity within 2–7 weeks. Full menstrual reinstatement occurred in 86% of participants (KD=3, KS=3), including those with long-standing amenorrhea. Ovulation was predicted in 43% of the cohort. Key metabolic improvements included significant insulin reductions, favorable body composition changes (fat mass loss with lean mass preservation), and enhanced neurobehavioral well-being, including reduced anxiety and improved cognitive clarity. Conclusion: Preliminary findings suggest that both sustained and intermittent ketogenic interven-tions can restore menstrual and ovulatory function through multi-node endo-crine-metabolic recovery, independent of significant weight loss. These results highlight the potential of ketogenic therapies for PMOS but require confirmation in larger trials.